<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02130063</url>
  </required_header>
  <id_info>
    <org_study_id>P-Monofer-IDA-01</org_study_id>
    <nct_id>NCT02130063</nct_id>
  </id_info>
  <brief_title>IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose</brief_title>
  <acronym>Provide</acronym>
  <official_title>A Phase III, Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose in Subjects With Iron Deficiency Anaemia and Who Are Intolerant or Unresponsive to Oral Iron Therapy or Who Need Iron Rapidly (PROVIDE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacosmos A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioStata</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ClinStar, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>LabCorp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmacosmos A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to evaluate and compare the effect of iron isomaltoside 1000 to
      iron sucrose in its ability to increase haemoglobin (Hb) in subjects with IDA when oral iron
      preparations are ineffective or cannot be used or where there is a clinical need to deliver
      iron rapidly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IDA is highly prevalent in subjects with gastrointestinal diseases and cancer, menstruating
      or pregnant women, and subjects who have undergone bariatric procedure. IDA can have a
      substantial medical and quality of life (QoL) burden on the subjects and the treatment of
      these subjects includes controlling the bleeding and replenishing lost iron. Oral iron
      administration is often used in the clinical practice at many clinics; however, oral iron may
      not be tolerated by all subjects. Hence, there is a need for an alternative iron treatment in
      subjects, who do not tolerate oral iron.

      This study is planned to compare the efficacy and safety of iron isomaltoside 1000 with
      another parenteral iron preparation (iron sucrose) in subjects with IDA and who are
      intolerant or unresponsive to oral iron therapy or who need iron rapidly.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With an Hb Increase of ≥ 2 g/dL From Baseline at Any Time From Week 1 to Week 5</measure>
    <time_frame>From baseline to week 5</time_frame>
    <description>The primary efficacy endpoint of the trial was the proportion of subjects with an Hb increase of ≥ 2 g/dL from baseline at any time from week 1 to week 5. 'Any time' implied that if the endpoint was met at a time-point prior to or at week 5, the effect (increase of ≥ 2 g/dL) did not have to be maintained throughout the trial in order for a subject to be a responder.
Number of responders (i.e. a subject with increase in Hb ≥ 2 g/dL from baseline at any time from week 1 to week 5) and percentages according to number of subjects in the analysis set were summarised.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hb Concentration</measure>
    <time_frame>From baseline to week 2, 4 and 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in S-ferritin Concentration</measure>
    <time_frame>From baseline to week 1, 2, 4, and 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TSAT</measure>
    <time_frame>From baseline to week 1, 2, 4, and 5</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">511</enrollment>
  <condition>Iron Deficiency Anaemia</condition>
  <arm_group>
    <arm_group_label>iron isomaltoside 1000 (Monofer®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>iron isomaltoside 1000 (Monofer®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iron sucrose (Venofer®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iron sucrose (Venofer®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iron isomaltoside 1000 (Monofer®)</intervention_name>
    <arm_group_label>iron isomaltoside 1000 (Monofer®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iron sucrose (Venofer®)</intervention_name>
    <arm_group_label>iron sucrose (Venofer®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women &gt; 18 years having IDA caused by different aetiologies such as abnormal
             uterine bleeding, gastrointestinal diseases, cancer, bariatric procedures (gastric
             bypass operations), and other conditions leading to significant blood loss and with a
             documented history of intolerance or unresponsiveness to oral iron therapy for at
             least one month prior to study enrollment or where there at investigators judgment is
             a clinical need to deliver iron rapidly

          2. Hb &lt; 11 g/dL

          3. TSAT &lt; 20 %

          4. S-ferritin &lt; 100 ng/mL

          5. Willingness to participate and signing the informed consent form

        Exclusion Criteria:

          1. Anaemia predominantly caused by factors other than IDA (e.g. anaemia with untreated
             vitamin B12 or folate deficiency, haemolytic anaemia)

          2. Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and
             haemosiderosis)

          3. Decompensated liver cirrhosis or active hepatitis (ALAT &gt; 3 times upper limit of
             normal)

          4. Active acute or chronic infections (assessed by clinical judgement supplied with white
             blood cells (WBC) and C-reactive protein (CRP))

          5. Body weight &lt; 50 kg

          6. Rheumatoid arthritis with symptoms or signs of active inflammation

          7. Pregnant or nursing women. In order to avoid pregnancy, women have to be surgically
             sterile or use adequate contraception (e.g. intrauterine devices, hormonal
             contraceptives, or double barrier method) during the whole study period and after the
             study has ended for at least 5 times plasma biological half-life of the
             investigational medicinal product

          8. History of multiple allergies

          9. Known hypersensitivity to parenteral iron or any excipients in the investigational
             drug products

         10. Erythropoietin treatment within 8 weeks prior to the screening visit

         11. Other iron treatment or blood transfusion within 4 weeks prior to the screening visit

         12. Planned elective surgery during the study

         13. Participation in any other clinical study within 3 months prior to the screening

         14. Any other medical condition that, in the opinion of Investigator, may cause the
             subject to be unsuitable for the completion of the study or place the subject at
             potential risk from being in the study, e.g. uncontrolled hypertension, unstable
             ischaemic heart disease, or uncontrolled diabetes mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2014</study_first_submitted>
  <study_first_submitted_qc>April 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2014</study_first_posted>
  <results_first_submitted>April 26, 2018</results_first_submitted>
  <results_first_submitted_qc>April 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 22, 2018</results_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IDA</keyword>
  <keyword>Iron deficiency</keyword>
  <keyword>iron deficiency anaemia and who are intolerant or unresponsive to oral iron therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric oxide, saccharated</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Iron Isomaltoside 1000 (Monofer®)</title>
          <description>iron isomaltoside 1000 (Monofer®)
iron isomaltoside 1000 (Monofer®)</description>
        </group>
        <group group_id="P2">
          <title>Iron Sucrose (Venofer®)</title>
          <description>iron sucrose (Venofer®)
iron sucrose (Venofer®)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="342"/>
                <participants group_id="P2" count="169"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="317"/>
                <participants group_id="P2" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>FAS (N = 491): The FAS consisted of all subjects who were randomised, received at least one dose of the trial drug, and had at least one post-baseline Hb assessment.</population>
      <group_list>
        <group group_id="B1">
          <title>Iron Isomaltoside 1000 (Monofer®)</title>
          <description>iron isomaltoside 1000 (Monofer®)
iron isomaltoside 1000 (Monofer®)</description>
        </group>
        <group group_id="B2">
          <title>Iron Sucrose (Venofer®)</title>
          <description>iron sucrose (Venofer®)
iron sucrose (Venofer®)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="342"/>
            <count group_id="B2" value="169"/>
            <count group_id="B3" value="511"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.3" spread="15.8"/>
                    <measurement group_id="B2" value="46.8" spread="14.9"/>
                    <measurement group_id="B3" value="48.4" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="309"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="463"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="342"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With an Hb Increase of ≥ 2 g/dL From Baseline at Any Time From Week 1 to Week 5</title>
        <description>The primary efficacy endpoint of the trial was the proportion of subjects with an Hb increase of ≥ 2 g/dL from baseline at any time from week 1 to week 5. ‘Any time’ implied that if the endpoint was met at a time-point prior to or at week 5, the effect (increase of ≥ 2 g/dL) did not have to be maintained throughout the trial in order for a subject to be a responder.
Number of responders (i.e. a subject with increase in Hb ≥ 2 g/dL from baseline at any time from week 1 to week 5) and percentages according to number of subjects in the analysis set were summarised.</description>
        <time_frame>From baseline to week 5</time_frame>
        <population>FAS (N = 491): The FAS consisted of all subjects who were randomised, received at least one dose of the trial drug, and had at least one post-baseline Hb assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Iron Isomaltoside 1000 (Monofer®)</title>
            <description>iron isomaltoside 1000 (Monofer®)
iron isomaltoside 1000 (Monofer®)</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose (Venofer®)</title>
            <description>iron sucrose (Venofer®)
iron sucrose (Venofer®)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With an Hb Increase of ≥ 2 g/dL From Baseline at Any Time From Week 1 to Week 5</title>
          <description>The primary efficacy endpoint of the trial was the proportion of subjects with an Hb increase of ≥ 2 g/dL from baseline at any time from week 1 to week 5. ‘Any time’ implied that if the endpoint was met at a time-point prior to or at week 5, the effect (increase of ≥ 2 g/dL) did not have to be maintained throughout the trial in order for a subject to be a responder.
Number of responders (i.e. a subject with increase in Hb ≥ 2 g/dL from baseline at any time from week 1 to week 5) and percentages according to number of subjects in the analysis set were summarised.</description>
          <population>FAS (N = 491): The FAS consisted of all subjects who were randomised, received at least one dose of the trial drug, and had at least one post-baseline Hb assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hb Concentration</title>
        <time_frame>From baseline to week 2, 4 and 5</time_frame>
        <population>FAS (N = 491): The FAS consisted of all subjects who were randomised, received at least one dose of the trial drug, and had at least one post-baseline Hb assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Iron Isomaltoside 1000 (Monofer®)</title>
            <description>iron isomaltoside 1000 (Monofer®)
iron isomaltoside 1000 (Monofer®)</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose (Venofer®)</title>
            <description>iron sucrose (Venofer®)
iron sucrose (Venofer®)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hb Concentration</title>
          <population>FAS (N = 491): The FAS consisted of all subjects who were randomised, received at least one dose of the trial drug, and had at least one post-baseline Hb assessment.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="1.03"/>
                    <measurement group_id="O2" value="0.87" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="1.32"/>
                    <measurement group_id="O2" value="1.74" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" spread="1.41"/>
                    <measurement group_id="O2" value="2.05" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in S-ferritin Concentration</title>
        <time_frame>From baseline to week 1, 2, 4, and 5</time_frame>
        <population>FAS (N = 491): The FAS consisted of all subjects who were randomised, received at least one dose of the trial drug, and had at least one post-baseline Hb assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Iron Isomaltoside 1000 (Monofer®)</title>
            <description>iron isomaltoside 1000 (Monofer®)
iron isomaltoside 1000 (Monofer®)</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose (Venofer®)</title>
            <description>iron sucrose (Venofer®)
iron sucrose (Venofer®)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in S-ferritin Concentration</title>
          <population>FAS (N = 491): The FAS consisted of all subjects who were randomised, received at least one dose of the trial drug, and had at least one post-baseline Hb assessment.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="431.2" spread="221.4"/>
                    <measurement group_id="O2" value="86.9" spread="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="516.6" spread="268.1"/>
                    <measurement group_id="O2" value="126.2" spread="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285.3" spread="205.2"/>
                    <measurement group_id="O2" value="195.0" spread="126.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241.2" spread="209.3"/>
                    <measurement group_id="O2" value="185.7" spread="166.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in TSAT</title>
        <time_frame>From baseline to week 1, 2, 4, and 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Isomaltoside 1000 (Monofer®)</title>
            <description>iron isomaltoside 1000 (Monofer®)
iron isomaltoside 1000 (Monofer®)</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose (Venofer®)</title>
            <description>iron sucrose (Venofer®)
iron sucrose (Venofer®)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in TSAT</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="9.6"/>
                    <measurement group_id="O2" value="3.3" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" spread="9.8"/>
                    <measurement group_id="O2" value="5.7" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" spread="9.0"/>
                    <measurement group_id="O2" value="11.5" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="8.6"/>
                    <measurement group_id="O2" value="11.8" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From screening until week 5</time_frame>
      <desc>An AE was described in the following manner: The nature of the event will be described in precise, standard medical terminology (i.e. not necessarily the exact words used by the subject). If known, a specific diagnosis was stated. Furthermore the Investigator described an AE regarding seriousness, severity, relatedness, and outcome.</desc>
      <group_list>
        <group group_id="E1">
          <title>Iron Isomaltoside 1000 (Monofer®)</title>
          <description>iron isomaltoside 1000 (Monofer®)
iron isomaltoside 1000 (Monofer®)</description>
        </group>
        <group group_id="E2">
          <title>Iron Sucrose (Venofer®)</title>
          <description>iron sucrose (Venofer®)
iron sucrose (Venofer®)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Stent malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Carcinoid tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Malignant mediastinal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Vith nerve paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Postpartum haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="333"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="333"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="333"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="333"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="333"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatique</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="333"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="333"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="333"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="333"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="333"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="333"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="333"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="333"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Pharmacosmos</organization>
      <phone>+45 5948 5959</phone>
      <email>llt@pharmacosmos.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

